Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYBN Cybin	$7.71 -4.1%	$7.30	$4.81 ▼ $13.88	$176.94M	0.68	266,485 shs	286,126 shs
GYRE Gyre Therapeutics	$8.09 +0.7%	$9.10	$6.11 ▼ $19.00	$749.12M	1.79	123,915 shs	86,117 shs
IOVA Iovance Biotherapeutics	$2.02 -2.9%	$2.51	$1.64 ▼ $12.51	$748.01M	0.86	8.90 million shs	7.85 million shs
REPL Replimune Group	$9.51 -3.3%	$8.70	$6.44 ▼ $17.00	$753.91M	0.63	888,466 shs	859,781 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYBN Cybin	-4.10%	-13.95%	+14.73%	+2.53%	+1,989.43%
GYRE Gyre Therapeutics	+0.75%	-10.11%	-28.72%	-21.30%	-29.84%
IOVA Iovance Biotherapeutics	-2.88%	-15.13%	+21.69%	-43.26%	-75.00%
REPL Replimune Group	-3.26%	-6.12%	+21.15%	-17.30%	+21.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYBN Cybin	2.5957 of 5 stars	3.6	0.0	0.0	2.6	0.8	1.3
GYRE Gyre Therapeutics	0.3318 of 5 stars	0.0	3.0	0.0	2.1	0.8	0.0
IOVA Iovance Biotherapeutics	4.5971 of 5 stars	4.3	1.0	4.2	1.7	4.2	1.3
REPL Replimune Group	4.5366 of 5 stars	3.6	3.0	4.5	3.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYBN Cybin	3.25	Buy	$86.00	1,015.43% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	558.42% Upside
REPL Replimune Group	3.14	Buy	$20.83	119.07% Upside

Current Analyst Ratings Breakdown

Latest CYBN, REPL, GYRE, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/13/2025	CYBN Cybin	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
GYRE Gyre Therapeutics	$105.76M	7.17	$0.20 per share	40.46	$1.05 per share	7.70
IOVA Iovance Biotherapeutics	$164.07M	4.11	N/A	N/A	$2.33 per share	0.87
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYBN Cybin	-$57.88M	-$4.38	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
GYRE Gyre Therapeutics	$12.09M	$0.02	404.70	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)

Latest CYBN, REPL, GYRE, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYBN Cybin	N/A	24.24	24.24
GYRE Gyre Therapeutics	N/A	3.60	3.19
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYBN Cybin	17.94%
GYRE Gyre Therapeutics	23.99%
IOVA Iovance Biotherapeutics	77.03%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
CYBN Cybin	15.00%
GYRE Gyre Therapeutics	10.00%
IOVA Iovance Biotherapeutics	10.30%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYBN Cybin	50	22.95 million	17.96 million	Not Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

CYBN, REPL, GYRE, and IOVA Headlines

Recent News About These Companies

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE

June 14, 2025 | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Wellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

June 3, 2025 | marketbeat.com

Piper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

June 2, 2025 | marketbeat.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

June 1, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

June 1, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?

May 31, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's Why

May 30, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC

May 30, 2025 | marketbeat.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

HC Wainwright Estimates Replimune Group Q3 Earnings

May 27, 2025 | marketbeat.com

Leerink Partnrs Estimates Replimune Group Q1 Earnings

May 27, 2025 | marketbeat.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LP

May 25, 2025 | marketbeat.com

Millennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 25, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Here's Why

May 24, 2025 | marketbeat.com

Traders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)

May 24, 2025 | marketbeat.com

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings

May 24, 2025 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYBN, REPL, GYRE, and IOVA Company Descriptions

Cybin NYSE:CYBN

$7.71 -0.33 (-4.10%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$7.74 +0.03 (+0.39%)

As of 06/17/2025 07:59 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Gyre Therapeutics NASDAQ:GYRE

$8.09 +0.06 (+0.75%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$8.07 -0.02 (-0.19%)

As of 06/17/2025 04:04 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$2.02 -0.06 (-2.88%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$2.02 +0.00 (+0.20%)

As of 04:39 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Replimune Group NASDAQ:REPL

$9.51 -0.32 (-3.26%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$9.54 +0.03 (+0.26%)

As of 04:01 AM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time